Cargando…

Meal-Related Changes in Apolipoprotein Particles After Treatment With an Antisense Oligonucleotide to Apolipoprotein CIII

Background: Lipodystrophy (LD) is defined by partial or complete absence of adipose tissue causing metabolic complications such as high triglycerides (TG). Apolipoprotein CIII (ApoCIII) contributes to high TG by inhibiting lipoprotein lipase (LPL). Measurement of lipoprotein particles using NMR can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brite, Brianna, Lightbourne, Marissa, Startzell, Megan S, Shamburek, Robert, Brown, Rebecca J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Cardiovascular Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089759/ http://dx.doi.org/10.1210/jendso/bvab048.596

Ejemplares similares

Volanesorsen, an Antisense Oligonucleotide to Apolipoprotein-CIII, Decreases Triglycerides and Increases Lipoprotein Lipase Activity in Partial Lipodystrophy
por: Lightbourne, Marissa, et al.
Publicado: (2021)

Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia
por: Guan, Yunpeng, et al.
Publicado: (2021)

SAT-081 Advanced Lipoprotein Analysis Demonstrates Atherogenic Lipid Profile in Patients with Lipodystrophy That Improves after Metreleptin Treatment
por: Kinzer, Alexandra, et al.
Publicado: (2019)

OR08-04 Differences in Advanced Lipoprotein Profile Between Rabson-Mendenhall Syndrome and Lipodystrophy
por: Al-Jundi, Mohammad, et al.
Publicado: (2020)

FRI117 Major Adverse Cardiovascular Events In Severe Insulin Resistance Syndromes: Lipodystrophy Compared To Pathogenic Variants Of The Insulin Receptor
por: Lightbourne, Marissa, et al.
Publicado: (2023)

Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes
por: HU, ZHI-JUAN, et al.
Publicado: (2014)

Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men
por: Faghihnia, Nastaran, et al.
Publicado: (2012)

Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
por: Valladolid-Acebes, Ismael, et al.
Publicado: (2021)

CD14(+)-Monocytes Exposed to Apolipoprotein CIII Express Tissue Factor
por: Olivieri, Oliviero, et al.
Publicado: (2023)

OR17-02 Changes in Hepatokines and Apolipoproteins Are Associated with Metabolic Response to Metreleptin in Partial Lipodystrophy
por: Akinci, Baris, et al.
Publicado: (2020)

Plasma Apolipoprotein CI and CIII Levels Are Associated With Increased Plasma Triglyceride Levels and Decreased Fat Mass in Men With the Metabolic Syndrome
por: van der Ham, Rachel L.M., et al.
Publicado: (2009)

Long Term Effects of Leptin on Hepatic Fibrosis in Generalized Lipodystrophy
por: Lightbourne, Marissa, et al.
Publicado: (2021)

Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells
por: Sol, E-ri M, et al.
Publicado: (2009)

Large-Scale Analysis of Apolipoprotein CIII Glycosylation by Ultrahigh Resolution Mass Spectrometry
por: Demus, Daniel, et al.
Publicado: (2021)

Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion
por: Zheng, Chunyu, et al.
Publicado: (2013)

Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism
por: Luo, Mengdie, et al.
Publicado: (2018)

Lowering apolipoprotein CIII protects against high-fat diet–induced metabolic derangements
por: Valladolid-Acebes, Ismael, et al.
Publicado: (2021)

Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids
por: Naber, Annemieke, et al.
Publicado: (2023)

OR17-01 Leptin Decreases De Novo Lipogenesis in Lipodystrophic Patients
por: Baykal, Annah Petek, et al.
Publicado: (2020)

SUN-087 Effects of Leptin Replacement on Circulating Plasma Inhibitors of Lipoprotein Lipase in Patients with Lipodystrophy
por: Lightbourne, Marissa, et al.
Publicado: (2019)

Apolipoprotein CIII Overexpressing Mice Are Predisposed to Diet-Induced Hepatic Steatosis and Hepatic Insulin Resistance
por: Lee, Hui-Young, et al.
Publicado: (2011)

The relationship between apolipoprotein CIII gene polymorphism and serum lipid levels in Han Chinese males()
por: Su, Shu, et al.
Publicado: (2013)

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
por: Taskinen, Marja-Riitta, et al.
Publicado: (2016)

Mass Spectrometry of Transferrin and Apolipoprotein CIII from Dried Blood Spots for Congenital Disorders of Glycosylation
por: Wada, Yoshinao, et al.
Publicado: (2022)

FRI107 Ketogenic Diet Prevents Development Of Atherosclerotic Plaques In Apolipoprotein E Knockout Mice
por: Marzolla, Vincenzo, et al.
Publicado: (2023)

SstI Polymorphism of the Apolipoprotein CIII Gene in Iranian Hyperlipidemic Patients: A Study in Semnan Province
por: Bandegi, Ahmad Reza, et al.
Publicado: (2011)

Association of serum lipids and coronary artery disease with polymorphisms in the apolipoprotein AI-CIII-AIV gene cluster
por: Rai, Himanshu, et al.
Publicado: (2016)

Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
por: Katzmann, Julius L., et al.
Publicado: (2020)

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
por: Geary, Richard S., et al.
Publicado: (2015)

MON-611 Biux2x2
por: Kushchayeva, Yevgeniya, et al.
Publicado: (2019)

Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death
por: Paiva, Adriene A., et al.
Publicado: (2017)

A Novel Role for RARα Agonists as Apolipoprotein CIII Inhibitors Identified from High Throughput Screening
por: Lee, Sang Jun, et al.
Publicado: (2017)

Apolipoprotein CIII Reduction Protects White Adipose Tissues against Obesity-Induced Inflammation and Insulin Resistance in Mice
por: Recio-López, Patricia, et al.
Publicado: (2021)

THU301 Natural History Of Pregnancy And Pregnancy Outcomes In Subjects With Lipodystrophy
por: Neal, Trinity J, et al.
Publicado: (2023)

Apolipoprotein CIII regulates lipoprotein-associated phospholipase A(2) expression via the MAPK and NFκB pathways
por: Han, Xiaolei, et al.
Publicado: (2015)

Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele
por: Olivieri, Oliviero, et al.
Publicado: (2013)

APOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the Metabolic Syndrome
por: Fallaize, Rosalind, et al.
Publicado: (2017)

Not Just Arterial Damage: Increased Incidence of Venous Thromboembolic Events in Cardiovascular Patients With Elevated Plasma Levels of Apolipoprotein CIII
por: Olivieri, Oliviero, et al.
Publicado: (2019)

Electrospray Ionization Mass Spectrometry of Apolipoprotein CIII to Evaluate O-glycan Site Occupancy and Sialylation in Congenital Disorders of Glycosylation
por: Wada, Yoshinao, et al.
Publicado: (2022)

SUN-565 The Effect of Leptin Treatment on Blood Pressure and Autonomic Nervous System Function in Patients with Lipodystrophy
por: Grover, Andrew, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4026hg3rdv53o1obbl57gb4fc5